NewsBenzingaNuvectis Pharma : BPA du T3 à (1,02 $), inférieur de 0,24 $ aux estimations Nuvectis Pharma : BPA du T3 à (1,02 $), inférieur de 0,24 $ aux estimations Benzinga 2026.11.04 12:11 (GMT+0) Open on Benzinga Other news Nvidia’s $105 Billion OpenAI Bet Has a 20-Year Catch Freedom Broker Upgrades Espey Manufacturing to Buy, Maintains Price Target to $70 QUICK SPARK: Chip Stocks Eye Worst Two-Month Drop Since 2008 Carlyle, Clearlake Bet Big On Sports — And PE Deals Are Surging Target's $301 Million Tariff Windfall 'Flattered' Earnings, Analyst Says Freedom Broker Maintains Buy on SKYX Platforms, Lowers Price Target to $2